Genome & Company (KOSDAQ:314130)

South Korea · Delayed Price · Currency is KRW

6,660.00

-250.00 (-3.62%)

At close: Apr 9, 2026

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Pharmaceuticals			14.30B	14.08B	451.25M	150.58M	45.83M
Pharmaceuticals Growth			1.50%	3021.27%	199.67%	228.54%	-
Total			14.30B	14.08B	451.25M	150.58M	45.83M
Total Growth			1.50%	3021.27%	199.67%	228.54%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
South Korea			2.39B	14.08B	451.25M	150.58M	45.83M
South Korea Growth			-83.06%	3021.27%	199.67%	228.54%	-
Asia			7.19B	-	-	-	-
Europe			269.13M	-	-	-	-
South America			15.04M	-	-	-	-
North America			4.39B	-	-	-	-
Oceania			52.16M	-	-	-	-
Total			14.30B	14.08B	451.25M	150.58M	45.83M
Total Growth			1.50%	3021.27%	199.67%	228.54%	-

Source: S&P Global Market Intelligence.